Tradjenta

Primary Use

Tradjenta is primarily prescribed to improve glycemic control in adults who have type 2 diabetes mellitus. It belongs to a class of drugs known as dipeptidyl peptidase-4 (DPP-4) inhibitors.

How It Is Used

This medication is typically used as part of a comprehensive treatment plan to manage blood sugar levels. Proper management of blood sugar is essential for reducing the risk of long-term health complications, such as:

• Kidney damage
• Blindness
• Nerve problems
• Loss of limbs
• Sexual dysfunction

Tradjenta is often used alone or in combination with other diabetes medications, such as metformin or insulin, when diet and exercise alone do not provide enough blood sugar control.

Limitations of Use

Tradjenta has specific limitations and is not appropriate for all types of diabetes or related conditions:

• Type 1 diabetes: It is not used to treat type 1 diabetes, a condition where the body does not produce insulin.
• Diabetic ketoacidosis: It should not be used to treat diabetic ketoacidosis, which is a serious condition involving high levels of ketones in the blood or urine.

It is also not known if Tradjenta is safe or effective for use in children under the age of 18.

Mechanism of Action

Tradjenta belongs to a class of medications known as dipeptidyl peptidase-4 (DPP-4) inhibitors. It works by regulating the levels of natural substances in the body called incretins.

The Role of Incretins

Incretin hormones are released by the intestines throughout the day, and their levels increase significantly after eating a meal. These hormones help the body manage blood sugar in two primary ways:

• Insulin Release: They signal the pancreas to produce and release more insulin when blood sugar levels are high.
• Glucose Regulation: They signal the liver to decrease the amount of sugar (glucose) it produces.

How Tradjenta Works

In a typical metabolic process, an enzyme called DPP-4 quickly breaks down incretin hormones. Tradjenta works by blocking this enzyme, which prevents the rapid breakdown of incretins. By allowing these hormones to remain active in the bloodstream for a longer period, Tradjenta helps the body more effectively lower blood sugar levels after eating and maintains better glucose balance throughout the day.

Because Tradjenta works by enhancing the body's natural response to rising blood sugar, it is used specifically for type 2 diabetes. It is not used to treat type 1 diabetes or diabetic ketoacidosis, as these conditions involve different underlying mechanisms regarding insulin production.

Common Side Effects

Some people may experience mild side effects while taking Tradjenta. These often include:

• Stuffy or runny nose
• Sore throat
• Cough
• Diarrhea

Serious Side Effects

Contact a healthcare provider immediately if you experience any of the following serious symptoms:

• Pancreatitis: Severe pain in the upper stomach that may spread to the back, which may occur with or without vomiting.
• Heart failure: Shortness of breath (especially when lying down), unusual tiredness, swelling in the legs, ankles, or feet, or sudden weight gain.
• Bullous pemphigoid: The development of blisters or the breakdown of the outer layer of skin.
• Severe joint pain: Intense or persistent pain in the joints.
• Allergic reactions: Swelling of the face, lips, tongue, or throat, skin rash, hives, or difficulty breathing and swallowing.

Low blood sugar (hypoglycemia) is a potential side effect, particularly when Tradjenta is used in combination with other diabetes medications like insulin or sulfonylureas. Symptoms of low blood sugar may include shakiness, sweating, rapid heartbeat, dizziness, and intense hunger.

Pancreatitis

Inflammation of the pancreas (pancreatitis) has occurred in people taking Tradjenta. This condition can be severe or life-threatening. Symptoms include persistent, severe abdominal pain that may radiate to the back, sometimes accompanied by vomiting. If pancreatitis is suspected, the medication is usually stopped immediately.

Heart Failure

There is an increased risk of heart failure with the use of DPP-4 inhibitors like linagliptin. This risk may be higher for individuals who already have heart or kidney problems. Signs of heart failure include shortness of breath, sudden weight gain, or swelling in the feet and legs.

Hypoglycemia (Low Blood Sugar)

While Tradjenta is unlikely to cause low blood sugar on its own, the risk increases significantly when it is used alongside other diabetes medications, such as insulin or sulfonylureas. A dosage adjustment of the other medications may be necessary to prevent hypoglycemia.

Severe Allergic Reactions

Serious hypersensitivity reactions have been reported. These include anaphylaxis, angioedema (swelling of the face, lips, or throat), and severe skin conditions. If a serious allergic reaction occurs, the medication is typically discontinued immediately and alternative treatments are considered.

Joint Pain and Skin Reactions

• Severe Joint Pain: Some patients experience disabling joint pain. This can occur shortly after starting the medication or months later. Symptoms usually resolve after stopping the drug.
• Bullous Pemphigoid: This is a serious skin reaction that causes large, fluid-filled blisters. It requires medical attention and usually involves stopping the medication.

Pregnancy

Data regarding the use of Tradjenta in pregnant women are limited and insufficient to determine if there is a drug-associated risk for major birth defects or miscarriage. Animal studies have generally not shown significant risks to the fetus at doses similar to those used in humans, but these results do not always predict human response.

Healthcare providers emphasize that poorly controlled diabetes during pregnancy poses risks to both the mother and the fetus, including preeclampsia, pregnancy loss, and delivery complications. Patients who are pregnant or planning to become pregnant should consult their doctor to determine the most appropriate treatment plan for managing blood sugar.

Breastfeeding

It is currently unknown if Tradjenta is present in human breast milk, how it affects a breastfed infant, or its impact on milk production. Animal studies have shown that the medication is excreted in the milk of lactating rats.

When deciding whether to breastfeed while taking this medication, the health benefits of breastfeeding should be weighed against the mother's clinical need for the drug and any potential risks to the infant. A healthcare professional can help evaluate these factors based on individual circumstances.

Available Forms

Tradjenta is supplied as a tablet for oral administration. The medication has the following physical characteristics:

• Form: Film-coated tablet
• Shape: Round and biconvex with beveled edges
• Appearance: Light red in color with identifying debossing on the surface

FDA Approval Status

Tradjenta, which contains the active ingredient linagliptin, was approved by the U.S. Food and Drug Administration (FDA) in May 2011. It belongs to a class of drugs called dipeptidyl peptidase-4 (DPP-4) inhibitors. It is indicated specifically for adults with type 2 diabetes and is not intended for the treatment of type 1 diabetes or diabetic ketoacidosis.

Safety Communications and Labeling Updates

The FDA has issued several safety communications and required label updates for the DPP-4 inhibitor class, including Tradjenta, based on post-marketing reports and clinical trials:

• Heart Failure Risk: The FDA required updates to the drug labels for DPP-4 inhibitors to include a warning about the risk of heart failure. This risk may be higher in patients who already have heart or kidney disease.
• Bullous Pemphigoid: The FDA identified a potential signal of risk for bullous pemphigoid, a skin condition that causes large, fluid-filled blisters. Labeling for Tradjenta includes information regarding this potential adverse reaction.
• Severe Joint Pain: In 2015, the FDA warned that DPP-4 inhibitors might cause joint pain that can be severe and disabling. Patients are advised to contact their healthcare provider if they experience persistent or severe joint pain while taking the medication.

Boxed Warnings and REMS

Tradjenta does not currently carry any FDA boxed warnings, which are the most serious warnings used for significant safety risks. There is also no Risk Evaluation and Mitigation Strategy (REMS) program required for this medication.

Insurance and Pharmacy Factors

The price of Tradjenta can vary based on your health insurance plan and its formulary. Your out-of-pocket costs are typically determined by your plan's co-pay or co-insurance requirements. Additionally, different pharmacies may offer varying retail prices for the medication.

Financial Assistance

Patients with commercial insurance may be eligible for manufacturer-sponsored savings cards or coupons to reduce their monthly costs. For those without insurance or with limited coverage, patient assistance programs may be available based on income and eligibility requirements.

Generic Availability

Tradjenta is a brand-name medication containing the active ingredient linagliptin. Generic versions are generally more affordable than brand-name drugs. You should speak with your pharmacist or healthcare provider to check for the current availability of generic linagliptin and how it might affect your treatment costs.